Drugs / DTap-HepB-IPV-Hib vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT05952596 Comparator | Jul → Oct 2023 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +2 | LG Chem | Unknown | No outcome recorded |
| Phase 1/2 | NCT06647407 Background | Nov 2024 → May 2027 expected | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTap-HepB-IPV-Hib vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06647407 ↗ |
| Modality | Vaccine | “Hexavalent vaccine” NCT05952596 ↗ |